Literature DB >> 15155246

Potential new anti-human immunodeficiency virus type 1 compounds depress virus replication in cultured human macrophages.

Gary D Ewart1, Najla Nasr, Hassan Naif, Graeme B Cox, Anthony L Cunningham, Peter W Gage.   

Abstract

We report that the amiloride analogues 5-(N,N-hexamethylene)amiloride and 5-(N,N-dimethyl)amiloride inhibit, at micromolar concentrations, the replication of human immunodeficiency virus type 1 (HIV-1) in cultured human blood monocyte-derived macrophages. These compounds also inhibit the in vitro activities of the HIV-1 Vpu protein and might represent lead compounds for a new class of anti-HIV-1 drugs.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15155246      PMCID： PMC415615          DOI： 10.1128/AAC.48.6.2325-2330.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release.

Authors:  T Klimkait; K Strebel; M D Hoggan; M A Martin; J M Orenstein
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

2.  Function of human immunodeficiency virus type 1 Vpu protein in various cell types.

Authors:  H Sakai; K Tokunaga; M Kawamura; A Adachi
Journal:  J Gen Virol       Date:  1995-11       Impact factor: 3.891

3.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

4.  A novel gene of HIV-1, vpu, and its 16-kilodalton product.

Authors:  K Strebel; T Klimkait; M A Martin
Journal:  Science       Date:  1988-09-02       Impact factor: 47.728

5.  Changes in the host range and growth potential of an HIV-1 clone are conferred by the vpu gene.

Authors:  B Du; A Wolf; S Lee; E Terwilliger
Journal:  Virology       Date:  1993-07       Impact factor: 3.616

6.  Rapid and efficient cell-to-cell transmission of human immunodeficiency virus infection from monocyte-derived macrophages to peripheral blood lymphocytes.

Authors:  J M Carr; H Hocking; P Li; C J Burrell
Journal:  Virology       Date:  1999-12-20       Impact factor: 3.616

7.  Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate.

Authors:  J W Balliet; D L Kolson; G Eiger; F M Kim; K A McGann; A Srinivasan; R Collman
Journal:  Virology       Date:  1994-05-01       Impact factor: 3.616

8.  Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses.

Authors:  H G Göttlinger; T Dorfman; E A Cohen; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

9.  Augmentation of virus secretion by the human immunodeficiency virus type 1 Vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes.

Authors:  U Schubert; K A Clouse; K Strebel
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

10.  The glyceraldehyde 3 phosphate dehydrogenase gene family: structure of a human cDNA and of an X chromosome linked pseudogene; amazing complexity of the gene family in mouse.

Authors:  A Hanauer; J L Mandel
Journal:  EMBO J       Date:  1984-11       Impact factor: 11.598
View more
  25 in total

Review 1.  The Vpu protein: new concepts in virus release and CD4 down-modulation.

Authors:  Autumn Ruiz; John C Guatelli; Edward B Stephens
Journal:  Curr HIV Res       Date:  2010-04       Impact factor: 1.581

Review 2.  Various plus unique: Viral protein U as a plurifunctional protein for HIV-1 replication.

Authors:  Andrew Soper; Guillermo Juarez-Fernandez; Hirofumi Aso; Miyu Moriwaki; Eri Yamada; Yusuke Nakano; Yoshio Koyanagi; Kei Sato
Journal:  Exp Biol Med (Maywood)       Date:  2017-01-01

3.  Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages.

Authors:  Gabriela Khoury; Gary Ewart; Carolyn Luscombe; Michelle Miller; John Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

4.  Entry of feline calicivirus is dependent on clathrin-mediated endocytosis and acidification in endosomes.

Authors:  Amanda D Stuart; T David K Brown
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

5.  Conformational changes induced by a single amino acid substitution in the trans-membrane domain of Vpu: implications for HIV-1 susceptibility to channel blocking drugs.

Authors:  Sang Ho Park; Stanley J Opella
Journal:  Protein Sci       Date:  2007-08-31       Impact factor: 6.725

6.  Modulation of the severe CD4+ T-cell loss caused by a pathogenic simian-human immunodeficiency virus by replacement of the subtype B vpu with the vpu from a subtype C HIV-1 clinical isolate.

Authors:  M Sarah Hill; Autumn Ruiz; Erik Pacyniak; David M Pinson; Nathan Culley; Bonnie Yen; Scott W Wong; Edward B Stephens
Journal:  Virology       Date:  2007-10-24       Impact factor: 3.616

7.  Requirements of the membrane proximal tyrosine and dileucine-based sorting signals for efficient transport of the subtype C Vpu protein to the plasma membrane and in virus release.

Authors:  Autumn Ruiz; M Sarah Hill; Kimberly Schmitt; John Guatelli; Edward B Stephens
Journal:  Virology       Date:  2008-06-24       Impact factor: 3.616

8.  Amiloride derivatives inhibit coxsackievirus B3 RNA replication.

Authors:  David N Harrison; Elena V Gazina; Damian F Purcell; David A Anderson; Steven Petrou
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

9.  Novel Acylguanidine-Based Inhibitor of HIV-1.

Authors:  Philip Mwimanzi; Ian Tietjen; Scott C Miller; Aniqa Shahid; Kyle Cobarrubias; Natalie N Kinloch; Bemuluyigza Baraki; Jonathan Richard; Andrés Finzi; David Fedida; Zabrina L Brumme; Mark A Brockman
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

10.  Targeting human immunodeficiency virus type 1 assembly, maturation and budding.

Authors:  Johanna Wapling; Seema Srivastava; Miranda Shehu-Xhilaga; Gilda Tachedjian
Journal:  Drug Target Insights       Date:  2007-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.